Omniox is an IND stage biotechnology company founded based on H-NOX technology developed in Michael Marletta’s laboratory at the University of California, Berkeley. We are developing the breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs where tissue hypoxia drives disease pathology and worsens patient outcomes. Our in-house team is composed of experienced scientific and biotechnology professionals, and our advisory boards include world-leading experts in the appropriate fields of medicine, science, and business. Omniox has received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors.
To pioneer innovative oxygen-based therapies that restore health to patients.
To solve difficult clinical problems where hypoxia plays a central role. Through rigorous science and world-class partnerships, we are developing our proprietary oxygen-delivery platform to provide meaningful therapeutic benefit to patients.
Rinko Ghosh joined Omniox as CEO in 2019. He has 21 years of experience in the Biopharmaceutical industry with a proven track record of executing high value transactions, raising funds, and building developmental/commercial expertise in entrepreneurial organizations. Previously he was President & CBO at Symic Bio (clinical-stage company developing compounds targeting the extra-cellular matrix). Prior to Symic, he was employed by Nektar Therapeutics for 13 years, serving in a variety of positions, including Senior Vice President & Chief Business Officer.
He has been affiliated with the licensing/development of more than 20 novel compounds, and has been an Advisor to several Life Sciences companies, including Epic Sciences, PulmoKine, MannKind, Pearl Therapeutics (acquired by Astra Zeneca), and Aviron (acquired by MedImmune/Astra Zeneca). He is a co-founder and Board Member at Tatara Therapeutics (an oncology company developing a pipeline of iron-sensing, targeted therapies). Earlier in his career, he worked as a management consultant with A.T. Kearney. He earned his M.B.A. from the Wharton School, University of Pennsylvania, his M.S. in Environmental Engineering from Vanderbilt University, and his B.S. in Chemical Engineering from the Indian Institute of Technology, Bombay.
VP Finance & Business Development
John Wesley joined Omniox in 2016 to lead business development and finance and has served on the board of directors since 2012. Prior to Omniox, John invested in public and private opportunities at Pequot Capital, H.I.G. Capital, and Concourse Capital. Prior to his investing career, John worked in strategic and financial advisory roles at Bain & Co. and Morgan Stanley. John received an MBA from the Wharton School and a B.S. in economics from Yale University. John is a CFA charterholder.
Co-Founder and VP Process Development & New Product Introduction
Jonathan Winger is co-inventor of the H-NOX technology and has 20+ years of experience with production and study of H-NOX and other proteins. At Omniox, he oversees the design, production, and characterization of protein variants with different kinetic and stability profiles, and manages process and analytical development for candidate H-NOX therapeutics. Prior to Omniox, Jonathan was an American Heart Association Postdoctoral Fellow at the University of California, Berkeley, where he used structural biology techniques including X-ray crystallography, small-angle X-ray scattering, and NMR to study H-NOX proteins, kinases, and other proteins. He obtained his PhD in Medicinal Chemistry at the University of Michigan, where he used spectroscopy and enzymology to study the role of soluble guanylate cyclase (sGC), an H-NOX-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox. Jonathan has published numerous research papers and abstracts, co-authored several book chapters, and is an inventor on multiple patents.
Director, Translational Research
Natacha Le Moan joined Omniox in 2012 and since 2015 has been Director of Translational Research. At Omniox, Natacha focuses on bridging pre-clinical model systems and clinical settings by leading multiple translational projects on ischemic disorders and neuro-oncology. Prior to joining Omniox, Natacha did her postdoctoral research at the University of California, San Francisco to study the role of hypoxia/ischemia in the nervous system using animal models of neurodegeneration. She is a neurobiologist with expertise in multiple aspects of ischemic and hypoxic signaling and has extensive experience in both the in vitro and in vivo approaches used to evaluate the efficacy of anti-hypoxia therapeutics in numerous animal models of neurological disorders. Natacha received her PhD from the University of Paris XI in France and has authored numerous peer reviewed scientific publications in prominent journals and is an inventor on multiple patents.
Senior Director, Biomarkers and Assay Development
Audrey Goddard joined Omniox in 2018 to lead biomarker and assay development, and is responsible for integration of drug and diagnostic research and development. Audrey has 26 years of industry experience at Genentech, Genomic Health, and uBiome; and was a Postdoctoral Fellow at London’s Imperial Cancer Research Fund. Audrey earned her Ph.D. in cancer genetics at the University of Toronto, has authored numerous peer reviewed scientific publications, and is an inventor on multiple patents.
Senior Director, Quality Assurance
Davis Bauman joined Omniox in 2018 and is responsible for leading Quality Assurance. He has more than 20 years of quality-related experience in positions with XOMA, Onyx Pharmaceuticals, Carbylan Therapeutics and Anthera Pharmaceuticals. Davis holds a bachelor’s degree in chemistry from Oberlin College.